Quick Takeaways: Why It Matters? The UK launch of Scovella (velagliflozin oral solution) creates the first licensed, equine‑specific treatment for hyperinsulinemia, directly targeting the main driver behind most laminitis cases and shifting management from off‑la...
Dechra Launches Domidine Equine Sedative in the US Quick Takeaways: Why It Matters? Dechra’s US launch of Domidine (detomidine) adds a generic, cost‑effective alpha‑2 agonist to the equine sedation market, giving veterina...
Quick Takeaways: Why It Matters? Parnell’s 50 mL PropofolVet Multidose should help veterinary practices match vial size to procedure volume, cutting waste and improving inventory efficiency while keeping the same propofol use cases and 28-day, no-refrigeration convenience. Marketwise, the ...
Quick Takeaways: Why It Matters? Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to kee...
Quick Takeaways: Why It Matters? Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a ...
Quick Takeaways: Why It Matters? Cronus Pharma is bringing price competition to a key canine heart failure drug class by launching the first FDA‑approved bioequivalent chewable to Vetmedin, available nationwide through vet distributors. For the market, this should lo...
